Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease.
Douangamath A, Fearon D, Gehrtz P, Krojer T, Lukacik P, Owen CD, Resnick E, Strain-Damerell C, Aimon A, Ábrányi-Balogh P, Brandão-Neto J, Carbery A, Davison G, Dias A, Downes TD, Dunnett L, Fairhead M, Firth JD, Jones SP, Keeley A, Keserü GM, Klein HF, Martin MP, Noble MEM, O'Brien P, Powell A, Reddi RN, Skyner R, Snee M, Waring MJ, Wild C, London N, von Delft F, Walsh MA. · 2020
Read Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. by Douangamath A, Fearon D, Gehrtz P, Krojer T, Lukacik P, Owen CD, Resnick E, Strain-Damerell C, Aimon A, Ábrányi-Balogh P, Brandão-Neto J, Carbery A, Davison G, Dias A, Downes TD, Dunnett L, Fairhead M, Firth JD, Jones SP, Keeley A, Keserü GM, Klein HF, Martin MP, Noble MEM, O'Brien P, Powell A, Reddi RN, Skyner R, Snee M, Waring MJ, Wild C, London N, von Delft F, Walsh MA. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7542442.txt.
Introduction
Douangamath and co-authors screen fragments against the SARS-CoV-2 main protease. This protease is vital for viral replication. No proven drugs existed for related coronaviruses at the time.
The team combined mass spectrometry with X-ray methods. They screened electrophile and non-covalent fragments at scale. Crystal work found 71 hits across the active site. Three more hits sat at the dimer interface. Some low-reactivity fragments were improved into stronger binders. Merging covalent and non-covalent hits offers a design route. The structures give rich data for drug design. Readers can see starting points for protease inhibitors in detail.
Catalog record
| CREATOR | Douangamath A, Fearon D, Gehrtz P, Krojer T, Lukacik P, Owen CD, Resnick E, Strain-Damerell C, Aimon A, Ábrányi-Balogh P, Brandão-Neto J, Carbery A, Davison G, Dias A, Downes TD, Dunnett L, Fairhead M, Firth JD, Jones SP, Keeley A, Keserü GM, Klein HF, Martin MP, Noble MEM, O'Brien P, Powell A, Reddi RN, Skyner R, Snee M, Waring MJ, Wild C, London N, von Delft F, Walsh MA. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease By Alice Douangamath, Daren Fearon, Paul Gehrtz, Tobias Krojer, Petra Lukacik, C David Owen, Efrat Resnick, Claire Strain-Damerell, Anthony Aimon, Péter Ábrányi-Balogh, José Brandão-Neto, Anna Carbery Published in: Nature Communications DOI: 10.1038/s41467-020-18709-w ABSTRACT Abstract COVID-19, caused by SARS-CoV-2, lacks effective therapeutics. Additionally, no antiviral drugs or vaccines were developed against the closely related coronavirus, SARS-CoV-1 or MERS-CoV, despite previous zoonotic outbreaks. To identify starting points for such therapeutics, we performed a large-scale screen of electrophile and non-covalent fragments through a combined mass spectrometry and X-ray approach against the SARS-CoV-2 main protease, one of two cysteine viral proteases essential for viral replication. Our crystallographic screen identified 71 hits that span the entire active site, as well as 3 hits at the dimer interface. These structures reveal routes to rapidly develop more potent inhibitors through merging of covalent and non-covalent fragment hits; one series of low-reactivity, tractable covalent fragments were progressed to discover improved binders. These combined hits offer unprecedented structural and reactivity information for on-going structure-based drug design against SARS-CoV-2 main protease. Subject terms: Enzymes, Proteases, Proteases, X-ray crystallography, Mass spectrometry INTRODUCTION A novel coronavirus, SARS-CoV-2, the causative agent of COVID-191–3, has resulted in over one million confirmed cases and in excess of 300,000 deaths across 188 countries as of mid-May 20204. SARS-CoV-2 is the third zoonotic coronavirus outbreak after the emergence of SARS-CoV-1 in 2002 and the Middle East Respiratory Syndrome (MERS-CoV) in 20125–7. SARS-CoV-2 is a large enveloped, positive-sense, single-stranded RNA Betacoronavirus. The viral RNA encodes two open reading frames that, through ribosome frame-shifting, generates two polyproteins pp1a and pp1ab8. These polyproteins produce most of the proteins of the replicase-transcriptase complex9. The polyproteins are processed by two viral cysteine proteases: a papain-like protease (PLpro) which cleaves three sites, releasing non-structural proteins nsp1-3 and a 3C-like protease, also referred to as the main protease (Mpro), that cleaves at 11 sites to release non-structural proteins (nsp4-16). These non-structural proteins form the replicase complex responsible for replication and transcription of the viral genome and have led to Mpro and PLPro being the primary targets for antiviral drug development10. Structural biology, which can play a key role in drug development, was also rapidly deployed after the 2002 SARS-CoV-1 outbreak, with earlier work by the Hilgenfeld group on Mpro of coronarviruses10 leading to crystal structures of SARS-CoV-1 Mpro and inhibitor complexes11–14. Active sites of Coronavirus Mpro are well conserved13,15–19, and those of enteroviruses (3Cpro) are functionally similar: this underpins ambitions to develop broad-spectrum antivirals. The most successful have been peptidomimetic α-ketoamide inhibitors20, with at least one potent variant seen as a potential antiviral drug19. Other studies have taken the popular approach of high-throughput screens (HTS) using very large compound libraries, followed by structural studies to elucidate the binding mode21. Despite these efforts, drugs remain elusive that directly target SARS-CoV-2 (rather than disease symptoms) and are verified by clinical trials. In retrospect, this is perhaps unsurprising for the Mpro inhibitors, as both peptidomimetic and covalent inhibition carry risks as strategies for drug development; in general, the simpler the molecule, the lower the risk. We therefore applied a different approach to Mpro, using fragment screening by high-throughput structural biology22. Fragment methods have become a staple of modern drug discovery23, using small collections (100 s or 1000 s) of small compounds (<300 Da) that bind promiscuously and thus sample a far larger chemical space than is achieved by HTS. The challenge is that the very weak binding of fragment hits necessitates highly sensitive biophysical detection, careful confirmation of binding and specialised medicinal chemistry expertise to advance hits to potency. Their promise is that potency can be achieved with high efficiency, simplifying the progression of molecules to biological or clinical impact. While the screening experiment itself has long relied on the high throughput of solution methods like NMR or SPR23, rapid advances in technology and automation at synchrotron radiation sources24 has made screening directly in crystal structures routinely possible at facilities like the XChem platform at Diamond Light Source25–28. These have been further enhanced by techniques such as mass spectrometry for the discovery of covalently binding fragments29. In the current study, we screened Mpro of SARS-CoV-2 with over 1250 unique fragments, identifying 74 high-value fragment hits, including 23 non-covalent and 48 covalent hits in the active site, and 3 hits at the vital dimerization interface. Here, these data are detailed along with potential ways forward for rapid follow-up design of improved, more potent, compounds. RESULTS Mpro crystallizes in a ligand-free form that diffracts to near-atomic resolution We report the apo structure of SARS-CoV-2 Mpro with data to 1.25 Å. The construct we crystallised has native residues at both N- and C--terminals, without cloning truncations or appendages which could otherwise interfere with fragment binding. Electron density is present for all residues, including 26 alternate conformations, many of which were absent in previous lower resolution crystal structures. The protein crystallised with a single protein polypeptide in the asymmetric unit, and the catalytic dimer is provided by a symmetry-related molecule. The structure aligns closely with the Mpro structures from SARS-CoV-1 and MERS (rmsd of 0.52 Å and 0.97 Å respectively). The active site is sandwiched between two β-barrel domains, I (residue 10–99) and II (residue 100–182) (Fig. 1a). Domain III (residue 198–306), forms a bundle of alpha helices and is proposed to regulate dimerization30. The C-terminal residues, Cys300-Gln306, wrap against Domain II. However, the C terminal displays a degree of flexibility and wraps around domain III in the N3 inhibitor complex30 (PDB ID 6LU7 [10.2210/pdb6lu7/pdb]). His41 and Cys145 comprise the catalytic dyad and dimerisation completes the active site by bringing Ser1 of the second dimer protomer into proximity with Glu166 (Fig. 1b). This aids formation of the substrate specificity pocket and the oxyanion hole10. Subsites have previously been identified in the active site based on interactions with peptide-based inhibitors and are shown in Fig. 1b19,31. Comparisons with peptide-based inhibitor complexes19,31 suggest a degree of active site plasticity. In particular, the C-alphas of Met49, Pro168, Gln189 respectively show movements of 2.8 Å, 1.4 Å, and 1.2 Å in comparison to the α-ketoamide inhibitor bound Mpro structure19 (PDB ID 6y2f [10.2210/pdb6y2f/pdb], Fig. 1c). [Figure: The crystal structure of ligand free Mpro is amenable to X-ray fragment screening.a Cartoon representation of the Mpro dimer. The nearmost monomer is shown with secondary structure features coloured to demarcate domains I, II, and III, in orange, cyan, and violet respectively. The active site of the rear monomer is indicated by the presence of a peptide-based inhibitor in green, generated by aligning the ligand-free structure with pdb 6Y2F [10.2210/pdb6y2f/pdb]. A yellow sphere indicates Ser1 from the dimer partner that completes the active site. b Residues of the active site are labelled, and subsites involved in ligand binding are shown with circles. c Active site plasticity is observed when comparing the apo structure to peptide inhibitor bound structures (green—Apo, grey—6Y2F [10.2210/pdb6y2f/pdb], pink 6LU7 [10.2210/pdb6lu7/pdb]). Displacement distances associated with loop movements are indicated.] The crystal form is well-suited for crystallographic fragment screening: although the percentage of solvent (~20%) is very low for a protein crystal, nevertheless clear channels are present that allow access to the active site through diffusion. Moreover,